Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 3
2013 6
2014 9
2015 20
2016 19
2017 14
2018 14
2019 10
2020 16
2021 17
2022 13
2023 12
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Palliative treatment of germ cell cancer.
Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J. Oing C, et al. Among authors: giannatempo p. Cancer Treat Rev. 2018 Dec;71:102-107. doi: 10.1016/j.ctrv.2018.10.007. Epub 2018 Oct 22. Cancer Treat Rev. 2018. PMID: 30415106 Free article. Review.
Erdafitinib for the treatment of urothelial cancer.
Marandino L, Raggi D, Giannatempo P, Farè E, Necchi A. Marandino L, et al. Among authors: giannatempo p. Expert Rev Anticancer Ther. 2019 Oct;19(10):835-846. doi: 10.1080/14737140.2019.1671190. Epub 2019 Oct 4. Expert Rev Anticancer Ther. 2019. PMID: 31544541 Review.
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P, Bottiglieri A, Rametta A, Taglialatela I, Vela C, Procopio G, Verzoni E. Fotia G, et al. Among authors: giannatempo p. Curr Oncol Rep. 2023 Jun;25(6):671-677. doi: 10.1007/s11912-023-01395-4. Epub 2023 Mar 31. Curr Oncol Rep. 2023. PMID: 37000341 Review.
Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Ottini A, et al. Among authors: giannatempo p. Per Med. 2022 Jan;19(1):51-66. doi: 10.2217/pme-2021-0079. Epub 2021 Dec 7. Per Med. 2022. PMID: 34873959 Review.
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study).
Procopio G, Sepe P, Claps M, Buti S, Colecchia M, Giannatempo P, Guadalupi V, Mariani L, Lalli L, Fucà G, de Braud F, Verzoni E. Procopio G, et al. Among authors: giannatempo p. JAMA Oncol. 2022 Jun 1;8(6):910-913. doi: 10.1001/jamaoncol.2022.0238. JAMA Oncol. 2022. PMID: 35420628 Free PMC article.
Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, Procopio G. Bottiglieri A, et al. Among authors: giannatempo p. Cancer Manag Res. 2022 Oct 21;14:3071-3081. doi: 10.2147/CMAR.S360441. eCollection 2022. Cancer Manag Res. 2022. PMID: 36275783 Free PMC article. Review.
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study.
Bogani G, Cinquini M, Signorelli D, Pizzutilo EG, Romanò R, Bersanelli M, Raggi D, Alfieri S, Buti S, Bertolini F, Bonomo P, Marandino L, Rizzo M, Monteforte M, Aiello M, Tralongo AC, Torri V, Di Donato V, Giannatempo P. Bogani G, et al. Among authors: giannatempo p. Crit Rev Oncol Hematol. 2023 Jul;187:104016. doi: 10.1016/j.critrevonc.2023.104016. Epub 2023 May 6. Crit Rev Oncol Hematol. 2023. PMID: 37156405 Review.
115 results